Alzheimer's Disease Clinical Trials in Arlington, TX

23 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	11 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	12 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	12 mi
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Phase 3	Suven Life Sciences Limited	12 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	18 mi
Clinical Trial on Agitation in Alzheimer's Dementia	Phase 2	IGC Pharma, LLC	18 mi
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease	N/A	InSightec	18 mi
Late Onset Alzheimer's Disease	—	Columbia University	18 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	18 mi
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Lantheus Biosciences Ltd.	18 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	18 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	18 mi
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease	Phase 2	Lighthouse Pharmaceuticals, Inc.	18 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	18 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	18 mi
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease	Phase 1/2	AbbVie	18 mi
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	Phase 2	Eli Lilly and Company	18 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	19 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	19 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	20 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)	Phase 3	Bristol-Myers Squibb	20 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	23 mi
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis	Phase 2	MapLight Therapeutics	43 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.